Sort
10,766 grants matching “checkpoint inhibitor”
The Impact of PD-1 Inhibition on Immune-Response to Chemoradiotherapy
$289,592Steven Francis Powell · Sanford Research/Usd · P20 · FY2019 · GM
Project 3
$289,491Michelle Krogsgaard · New York University School Of Medicine · P50 · FY2021 · CA
Res Proj 2: Molecular Imaging Strategies to Study Cdc25A Regulation in vivo
$289,482Helen M Piwnica-Worms · Washington University · P50 · FY2010 · CA
Role of PI3Kinase in Tumor Progression and Metastasis
$289,463Judith A. Varner · University Of California, San Diego · R01 · FY2022 · CA
PROTEOLYSIS AND MAMMALIAN GL/S CELL CYCLE TRANSITION
$289,151Yale University · R01 · FY2001 · CA
The Impact of PD-1 Inhibition on Immune-Response to Chemoradiotherapy
$288,946Steven Francis Powell · Sanford Research/Usd · P20 · FY2020 · GM
DNA DAMAGE RESPONSE AND DNA REPLICATION
$288,778Columbia University Health Sciences · R01 · FY2004 · CA
DNA DAMAGE RESPONSE AND DNA REPLICATION
$288,778Columbia University Health Sciences · R01 · FY2003 · CA
DNA DAMAGE RESPONSE AND DNA REPLICATION
$288,778Columbia University Health Sciences · R01 · FY2002 · CA
Molecular targeting of the survivin pathway in cancer
$288,775Dario C. Altieri · Univ Of Massachusetts Med Sch Worcester · R01 · FY2007 · CA
Molecular targeting of the survivin pathway in cancer
$288,775Dario C. Altieri · Univ Of Massachusetts Med Sch Worcester · R01 · FY2010 · CA
Molecular targeting of the survivin pathway in cancer
$288,775Dario C. Altieri · Univ Of Massachusetts Med Sch Worcester · R01 · FY2009 · CA
Molecular targeting of the survivin pathway in cancer
$288,775Dario C. Altieri · Univ Of Massachusetts Med Sch Worcester · R01 · FY2008 · CA
Metabolic regulation of epigenetic states in CD8 T cell exhaustion
$288,600Susan M Kaech · Salk Institute For Biological Studies · R21 · FY2021 · AI
Clinical & Mechanistic underpinnings to reducing PAX:FOXO1 for alveolar rhabdomyosarcoma
$288,592Charles Keller · Children'S Cancer Therapy Develop/Inst · R01 · FY2024 · CA
Project 1: Treatment of GBM using an oncolytic HSV engineered to improve immunogenic tumor destruction
$288,477Joseph C. Glorioso · Brigham And Women'S Hospital · P01 · FY2024 · CA
Simultaneous Radiotherapy with PD-1 and IDO1 Blockade for Overcoming Immune Suppression in Glioblastoma
$288,421Derek Alan Wainwright · Northwestern University At Chicago · P50 · FY2022 · CA
Project 1: Targeted sequencing and clinicopathology to evaluate primary melanoma molecular subtypes and outcomes
$288,413Marianne Berwick · University Of New Mexico Health Scis Ctr · P01 · FY2019 · CA
Biostatistics and Data Management
$288,360Haesook Kim · Dana-Farber Cancer Inst · P01 · FY2021 · CA
Biostatistics and Data Management
$288,360Haesook Kim · Dana-Farber Cancer Inst · P01 · FY2020 · CA
Biostatistics and Data Management
$288,360Haesook Kim · Dana-Farber Cancer Inst · P01 · FY2019 · CA
Project 4
$288,300Eva Hernando · New York University School Of Medicine · P50 · FY2020 · CA
Flow Cytometry and Technology Development
$288,205Victor M Lemas · Johns Hopkins University · P30 · FY2023 · CA
Flow Cytometry and Technology Development
$288,205Victor M Lemas · Johns Hopkins University · P30 · FY2022 · CA
Flow Cytometry and Technology Development
$288,205Victor M Lemas · Johns Hopkins University · P30 · FY2024 · CA